

DFW

Docket No.: SC66U-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ralph R. Binetti, et al.
Serial No. : 10/738,413 Group Art Unit: 1635
Filed : December 17, 2003 Examiner: Bowman, Amy Hudson
For : si-RNA-MEDIATED GENE SILENCING TECHNOLOGY TO INHIBIT
TYROSINASE AND REDUCE PIGMENTATION

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is:

1. Transmittal Letter (1 page);
2. Response to Restriction and election Requirements (2 pages);
3. Return postcard.

Please charge any additional fees or credits any such fees, if necessary to Deposit Account No. 01-3040 in the name of Avon Products, Inc. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: August 17, 2005

Charles J. Zeller, Esq.
Associate Attorney for Inventors
Reg. No. 28,682
AVON PRODUCTS, INC.
Avon Place
Suffern, New York 10901
Tel: 845-369-2113
Fax: 845-369-2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Kathy S. Abrams

SIGNATURE

8/19/05
DATE



Docket No. SC66U-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ralph R. Binetti, et al.

Group Art Unit: 1635

Serial No.: 10/738,413

Examiner: Bowman, Amy Hudson

Filed: December 17, 2003

For: si-RNA-MEDIATED GENE SILENCING TECHNOLOGY TO INHIBIT
TYROSINASE AND REDUCE PIGMENTATION

RESPONSE TO RESTRICTION AND ELECTION REQUIREMENTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madame:

This is in response to the Office Action dated July 20, 2005, having a one (1) month period set for reply.

REMARKS

Pursuant to 35U.S.C. 121, the Office Action requested Applicant to restrict prosecution on the merits to one of the following groups:

- I. Claims 1-15, drawn to a method of treating hyperpigmentation or other unwanted pigmentation or skin condition, comprising topically administering a composition comprising one or more siRNA oligomers specific for tyrosinase mRNA in an effective amount to prevent, ameliorate, reduce, and/or eliminate the unwanted skin condition, classified in class 514, subclass 44;
- II. Claims 31-39, drawn to a method of treating, preventing, reducing, ameliorating, and/or eliminating hyperpigmentation or other unwanted pigmentation, comprising provided a composition comprising an siRNA oligomer specific for